Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CEA CAR-T hepatic infusions in pancreatic carcinoma
NCT03818165Phase 1Terminated
- Sponsor
- Sorrento Therapeutics
- Start
- Jul 2019
- Primary completion
- Jan 2020
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CAR2 anti-CEA CAR-T cells in pancreatic carcinoma, sponsored by Sorrento Therapeutics. Primary endpoint: Overall Survival at 6 months. Started Jul 2019; status: terminated.
02
Drugs
CAR2 anti-CEA CAR-T cells
03
Conditions
pancreatic carcinoma
Beyond the preview
Go deeper on NCT03818165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03818165.